Dapagliflozin is a pharmaceutical agent indicated for the management of type 2 diabetes, heart failure, and chronic kidney disease (CKD). It belongs to the class of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, which have proven effective in lowering blood glucose levels and offering additional cardiovascular and renal benefits. Mechanism of Action of …
Read More »